Deferasirox vs deferoxamine: AE: Serum creatinine increase
Deferasirox showed no clear difference in AE: Creatinine increase compared with deferoxamine (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Deferasirox vs Deferoxamine AE: Creatinine increase · patients with managing transfusional iron overload in people with sickle cell disease Deferasirox showed no clear difference in AE: Creatinine increase compared with deferoxamine (moderate certainty). Deferasirox for managing transfusional iron overload in people with sickle cell disease (2010) · Cochrane Headline outcomes onlyearlier version CD007477.PUB2, superseded | RR 1.64 [0.98, 2.74] | 1 study · 195 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Deferasirox for managing transfusional iron overload in people with sickle cell disease 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.